NRC Briefing on Proposed Rule on Part 35 Medical Events Definition-Permanent Implant Brachytherapy

July 8, 2010
Brian J. Davis, M.D., Ph.D.
American Brachytherapy Society –
Past Chairman (2009-2010)
President (2008-2009)
Associate Professor, Mayo Clinic

REPROPOSED RULE: AMENDMENTS/MEDICAL EVENT DEFINITIONS (RIN 3150- AI26)

- Can the AU Revise the Pre-implantation WD After Beginning the Administration of Brachytherapy?
- No(!??). Once the administration of brachytherapy has begun no changes may be made to the preimplantation WD. As is also provided by the current regulations, revisions to the WD must be made before implantation begins. The reason the preimplantation WD cannot be changed is that the preimplantation WD serves as one of the bases for determining if an ME has occurred.

REPROPOSED RULE: AMENDMENTS/MEDICAL EVENT DEFINITIONS (RIN 3150- AI26)

 However, § 35.40(c) allows for an existing WD to be revised by an AU prior to beginning the administration in order to account for any changes in the treatment site (such as organ volume and shape) that may have occurred between the time of planning the treatment and the implantation procedure.

3


REPROPOSED RULE: AMENDMENTS/MEDICAL EVENT DEFINITIONS (RIN 3150- AI26)


- Why is this wrong?
 - Volume change after a permanent seed implant is unpredictable, so a dose determination at a single time point may easily vary by more than an arbitrary 20%.
 - It will result in an over-reporting of ME's without any justifiable clinical basis.
 - Excellent long-term results are reported for cases where intended dose prior to an implant varies by more than 20% after an implant.


REPROPOSED RULE: AMENDMENTS/MEDICAL EVENT DEFINITIONS (RIN 3150- AI26)


- Is delivering a +/- 20% dose in permanent prostate brachytherapy routinely achievable?
- Is it necessary?


5














Conclusions

- Permanent prostate implants produce excellent results even with >20% variation from treated to planned dose to the prostate.
- The ACMUI recommendations are most consistent with the American Brachytherapy Society guidelines and current practice at the Mayo Clinic.